Litigation

Celgene Corporation v. Lannett Holdings, Inc.

settled

2:15-cv-00697

Filed
2015-01-30

Patents at issue (2)

Summary

Celgene filed an ANDA patent infringement action against Lannett over generic thalidomide (Lannett ANDA No. 206601), asserting fifteen patents. The parties settled in 2017, with Lannett converting its Paragraph IV certification on the '745 patent to a Paragraph III certification and receiving a license to market generic thalidomide as of August 1, 2019. The narrative could not confirm that U.S. 7,959,566 was among the fifteen asserted patents.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).